Asthma exacerbations and worsenings in patients aged 1-75 years with add-on tiotropium treatment

被引：6

作者：

FitzGerald, J. Mark ^{[1
]}

Hamelmann, Eckard ^{[2
,3
]}

Kerstjens, Huib A. M. ^{[4
,5
]}

Buhl, Roland ^{[6
]}

机构：

[1] Ctr Heart & Lung Hlth, Vancouver, BC, Canada

[2] Evangel Klinikum Bethel, Klin Kinder & Jugendmed, Bielefeld, Germany

[3] Ruhr Univ, Allergy Ctr, Bochum, Germany

[4] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol & TB, Groningen, Netherlands

[5] Groningen Res Inst Asthma & COPD GRIAC, Groningen, Netherlands

[6] Johannes Gutenberg Univ Hosp Mainz, Pulm Dept, Mainz, Germany

来源：

NPJ PRIMARY CARE RESPIRATORY MEDICINE | 2020年 / 30卷 / 01期

关键词：

D O I：

10.1038/s41533-020-00193-w

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

This review explores the effect of tiotropium Respimat (R) add-on therapy on asthma exacerbations and worsenings, adverse events (AEs) related to exacerbations and symptoms and any effects on seasonality across the 10 UniTinA-asthma (R) clinical trials comprising over 6000 patients. When added on to inhaled corticosteroids +/- additional therapies, tiotropium significantly reduced the risk of exacerbations and worsenings in adults with symptomatic severe asthma and provided a non-significant improvement in worsenings in adults with symptomatic moderate and mild asthma, which was significant for patients with moderate asthma receiving tiotropium 2.5 mu g once daily vs. placebo. Trials in paediatric patients were not powered to assess exacerbations or worsenings, but when AEs related to asthma exacerbations and symptoms were grouped into a composite endpoint and pooled, tiotropium improved outcomes vs. placebo (rate ratio 0.76; 95% confidence interval 0.63, 0.93). The reduction in exacerbations with tiotropium is apparent across all patients during the observed seasonal peaks of these events.

引用

页数：10

共 45 条

[1]

Balter Meyer, 2008, Can Respir J, V15 Suppl B, p1B

[2]

Boehringer Ingelheim Limited, 2018, SPIR RESP 2 5 MICR I

[3]

Boehringer Ingelheim Pharmaceuticals Inc, 2019, SPIRIVA R RESPIMAT R

[4] Researching asthma across the ages: Insights from the National Heart, Lung, and Blood Institute's Asthma Network [J].

Cabana, Michael D. ;

Kunselman, Susan J. ;

Nyenhuis, Sharmilee M. ;

Wechsler, Michael E. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (01) :27-33

[5] Managing asthma exacerbations in the emergency department: Summary of the National Asthma Education and Prevention Program Expert Panel Report 3 guidelines for the management of asthma exacerbations [J].

Camargo, Carlos A., Jr. ;

Rachelefsky, Gary ;

Schatz, Michael .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 124 (02) :S5-S14

[6]

ClinicalTrials.gov, 2010, EFF SAF 2 DOS TIOTR

[7]

ClinicalTrials.gov, 2008, EV TIOTR 5 MU G DAY

[8]

ClinicalTrials.gov, 2012, EV TIOTR 2 5 5 MCG O

[9]

ClinicalTrials.gov, 2011, EFF SAF 2 DOS TIOTR

[10]

ClinicalTrials.gov, 2010, EV TIOTR 2 5 5 MCG O

← 1 2 3 4 5 →